PRIMA-1 synergizes olaparib-induced cell death in p53 mutant triple negative human breast cancer cell line via restoring p53 function, arresting cell cycle, and inducing apoptosis

Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)

(2022) Chetan C. Oturkar et al.   Cancers

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phenethyl Isothiocyanate Induces Apoptosis Through ROS Generation and Caspase-3 Activation in Cervical Cancer Cells

(2021) Shoaib Shoaib et al.   Frontiers in Pharmacology

Pantoprazole abrogated cisplatin-induced nephrotoxicity in mice via suppression of inflammation, apoptosis, and oxidative stress

(2020) Raed S. Ismail et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

State-of-the-art strategies for targeting the DNA damage response in cancer

(2018) Patrick G. Pilié et al.   Nature Reviews Clinical Oncology

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

(2017) Anne Perdrix et al.   Cancers

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety

(2016) U. A. Matulonis et al.   ANNALS OF ONCOLOGY

APR-246 (PRIMA-1 MET ) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

(2016) Christophe Deben et al.   CANCER LETTERS

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

(2016) N.C. Synnott et al.   INTERNATIONAL JOURNAL OF CANCER

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair

(2014) P. Jelinic et al.   MOLECULAR CANCER THERAPEUTICS

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

p53 regulates a non-apoptotic death induced by ROS

(2013) J Montero et al.   CELL DEATH AND DIFFERENTIATION

p53 talks to PARP: the increasing complexity of p53-induced cell death

(2013) K G Wiman   CELL DEATH AND DIFFERENTIATION

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

PARP and Cancer — If It's Broke, Don't Fix It

(2011) Lisa A. Carey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Agents and Future Directions for Refractory Breast Cancer

(2011) Harold J. Burstein   SEMINARS IN ONCOLOGY

Targeting DNA repair in breast cancer: A clinical and translational update

(2010) Eitan Amir et al.   CANCER TREATMENT REVIEWS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Blinded by the Light: The Growing Complexity of p53

(2009) Karen H. Vousden et al.   CELL

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE